Tagged with Roche

Global In conversation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 in Madrid, Roche Diagnostics’ Margherita Carboni discusses the potential of blood-based biomarkers to transform Alzheimer’s diagnostics, offering a faster and less invasive alternative to traditional methods. She highlights Roche’s commitment to ensuring diversity in clinical trials, a crucial step in…

Mexico Monica Palomanes, General Manager of Roche Mexico, discusses her journey within the company and the shift from traditional sales to a collaborative approach with Patient Journey Partners. She addresses challenges in access and diagnosis within Mexico’s fragmented healthcare system, while recognising the country’s potential for clinical research due to the…

Switzerland Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European counterparts when it comes to healthcare digitalisation. Recent PharmaBoardroom interviewees weigh in on the country’s digital lag, its electronic patient…

Switzerland Katharina Gasser of Roche Pharma Switzerland lays out her dedication to fostering innovation, strengthening team dynamics, and influencing the future of Switzerland’s healthcare landscape. Gasser emphasizes the need to combat complacency, advance digitalization, and promote diversity in leadership, noting that “complacency is a real threat—it stifles innovation, diminishes drive, and…

Hong Kong Ronald Lo, general manager of Roche Diagnostics Hong Kong shares some of company’s advances in diagnostic disease prevention that are particularly revelant in Hong Kong, such as its recently FDA-approved HPV self-sampling in a territory where only 52 percent of women have ever done cervical screening, and in light of…

Mexico Joao Carapeto outlines Roche Diagnostics’ commitment to innovation, prevention, and diagnostics, emphasizing the need for robust partnerships and increased investment in early detection to address Mexico’s healthcare challenges. He highlights the significance of managing an aging population and improving the quality of life through advanced healthcare solutions.   Prevention and…

Mexico This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In some cases, the appointments represent a first for affiliates that have never had female leaders while in others they coincide…

Global As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other shifts as reflected in Pharma Exec’s 2024 Top 50 Companies. Based on 2023 drug revenue performance from global drug makers,…

Hong Kong Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines its growing local clinical research commitment, one that has seen its clinical trial activities increase 2.5 times and reach an…

Switzerland The latest news from Swiss pharma and biotech including a new CEO appointment for leading CDMO Lonza, promising Phase III readouts from Novartis’ latest leukaemia drug at ASCO, Roche’s pivot to obesity, and why the Swiss industry is betting big on artificial intelligence.   Lonza appoints Wolfgang Wienand as new…

Switzerland The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and the licence agreement between EraCal Therapeutics and Novo Nordisk.   Swiss industry welcomes agreement with India, pharma more cautious (Le…

Portugal The top 10 pharma companies in Portugal ranked by sales value in both the hospital and pharmacy markets. These charts are from IQVIA and are based on a moving annual total up to October 2023. Household Big Pharma names like Janssen (recently rebranded as Johnson & Johnson Innovative Medicines), Roche,…